Although synergistic antileukemic interactions between CUDC-907 and gilteritinib could also be detected in certain FLT3-wt AML cells, potentially due to downregulation of wild-type FLT3 by CUDC-907 and inhibition of the receptor tyrosine kinase by gilteritinib, the detailed molecular mechanism remains to be determined. The gene discussed is FLT3; the disease is acute myeloid leukemia.